BioNTech, a next-generation immunotherapy company, agreed to invest $200m in Autolus Therapeutics, a clinical-stage biopharmaceutical company. “The collaboration with Autolus enables us to expand our BNT211 program into trials for multiple cancer indications in a cost-efficient way. Autolus' state-of-the-art manufacturing facilities’ set-up for clinical and commercial supply will enhance our own capacities in addition to our existing US supply network and the ongoing expansion of our site in Gaithersburg, Maryland. Furthermore, this collaboration grants us access to Autolus' precise cell targeting tools to further support BioNTech’s development of in vivo cell therapy and antibody-drug conjugate candidates," Ugur Sahin, BioNTech Managing Director, CEO and Co-Founder.